PROpel and Cilostazol to Prevent Paclitaxel Neuropathy
Jun 01, 2023•17 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Olaparib + Abiraterone is FDA approved for mutated-BRCA prostate cancers. Olaparib has a bit of convoluted story to unpack in this patient population.
Have we finally found a way to minimize the peripheral neuropathy from paclitaxel.....with cilostazol?
PROpel: https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200043
Cilostazol RCT: https://doi.org/10.1002/phar.2830
Cilostazol effect on Schwann cells: https://doi.org/10.1016/j.neuropharm.2021.108514
For the best experience, listen in Metacast app for iOS or Android